ArticleThe European respiratory journal2016
Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden.
Article in The European respiratory journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Clinical effectiveness and impact of 13-valent pneumococcal conjugate vaccines in preventing invasive pneumococcal disease among children with risk conditions: A systematic literature review.Human vaccines & immunotherapeutics · 2026Pooled it
- Serotype distribution and antimicrobial resistance patterns of invasive pneumococcal disease isolates from children in mainland China-a systematic review.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2020Pooled it
- Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine (PCV-15) compared to PCV-13 in healthy older adults.Human vaccines & immunotherapeutics · 2019Trial
- Prevalence, Serotype Distribution, and Risk Factors Associated WithOpen forum infectious diseases · 2026Article
- Pneumococcal membrane particles promote serotype-independent cellular and humoral immunity and protect against pneumococcal colonization.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Genomic characterization of invasive disease-causingMicrobial genomics · 2026Article
- Article
- Community-acquired bacterial meningitis in Southern Sweden 2013-2023: a population-based study of incidence, aetiology and diagnostic yield.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- Article
- The resilience of vaccine serotypes in adult invasive pneumococcal disease in Portugal, 2018-2023.Scientific reports · 2025Article
- Review
- Serotype specific pneumococcal vaccine effectiveness in children with sickle cell disease: A two-decade analysis.Vaccine · 2025Article
- Streptococcus pneumoniae epidemiology, pathogenesis and control.Nature reviews. Microbiology · 2025Review
- A literature review and evidence-based evaluation of the Dutch national immunisation schedule yield possibilities for improvements.Vaccine: X · 2024Review
- Antimicrobial Resistance ofInfection & chemotherapy · 2024Article
- Pneumococcal serotypes and risk factors in adult community-acquired pneumonia 2018-20; a multicentre UK cohort study.The Lancet regional health. Europe · 2024Article
- Article
- Combinatorial multimer staining and spectral flow cytometry facilitate quantification and characterization of polysaccharide-specific B cell immunity.Communications biology · 2023Article
- Immunization with Attenuated Pneumococcal Strains Provides Protection against Pneumococcal Colonization in Humans.American journal of respiratory and critical care medicine · 2023Article
- Pneumococcal Serotype Evolution and Burden in European Adults in the Last Decade: A Systematic Review.Microorganisms · 2023Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effects of pneumococcal conjugated vaccines (PCVs) need to be investigated. In Stockholm County, Sweden, PCV7 was introduced in the childhood immunisation programme in 2007 and changed to PCV13 in 2010.Over 90% of all invasive isolates during 2005-2014 (n=2336) and carriage isolates, 260 before and 647 after vaccine introduction, were characterised by serotyping, molecular typing and antibiotic susceptibility, and serotype diversity was calculated. Clinical information was collected for children and adults with invasive pneumococcal disease (IPD).The IPD incidence decreased post-PCV7, but not post-PCV13, in vaccinated children. Beneficial herd effects were seen in older children and adults, but not in the elderly. The herd protection was more pronounced post-PCV7 than post-PCV13. PCV7 serotypes decreased. IPD caused by PCV13 serotypes 3 and 19A increased post-PCV7. Post-PCV13, serotypes 6A and 19A, but not serotype 3, decreased. The serotype distribution changed in carriage and IPD to nonvaccine types, also in nonvaccinated populations. Expansion of non-PCV13 serotypes was largest following PCV13 introduction. Serotype diversity increased and nonvaccine clones emerged, such as CC433 (serotype 22F) in IPD and CC62 (serotype 11A) in carriage. In young children, meningitis, septicaemia and severe rhinosinusitis, but not bacteraemic pneumonia, decreased.Pneumococcal vaccination leads to expansion of new or minor serotypes/clones, also in nonvaccinated populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.